Open Actively Recruiting

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

About

Brief Summary

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
24-5096
Category
Other Cancer
Contact
Bruck Habtemariam
Location
  • UCLA Torrance
  • UCLA Westwood
For Providers
NCT No.
NCT06196203
For detailed technical eligibility, visit ClinicalTrials.gov.